Ultragenyx Pharmaceutical's mixed Q2 results have led to a decrease in its share price. This indicates that the market had higher expectations for the company's performance. The direct mention of the company and its performance results in a high relevance score. The importance is also high due to the potential impact on investor decisions. The confidence in this analysis is high as it is based directly on the information provided in the news.